Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Gross Profit: 2009-2024

Historic Gross Profit for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to $475.4 million.

  • Amicus Therapeutics' Gross Profit rose 16.65% to $149.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $537.5 million, marking a year-over-year increase of 20.99%. This contributed to the annual value of $475.4 million for FY2024, which is 31.30% up from last year.
  • Amicus Therapeutics' Gross Profit amounted to $475.4 million in FY2024, which was up 31.30% from $362.0 million recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' Gross Profit registered a high of $475.4 million during FY2024, and its lowest value of $229.8 million during FY2020.
  • Over the past 3 years, Amicus Therapeutics' median Gross Profit value was $362.0 million (recorded in 2023), while the average stood at $376.0 million.
  • Data for Amicus Therapeutics' Gross Profit shows a peak YoY surged of 43.41% (in 2020) over the last 5 years.
  • Over the past 5 years, Amicus Therapeutics' Gross Profit (Yearly) stood at $229.8 million in 2020, then grew by 17.93% to $271.0 million in 2021, then rose by 7.23% to $290.6 million in 2022, then climbed by 24.57% to $362.0 million in 2023, then soared by 31.30% to $475.4 million in 2024.